HYPR

0.54654.27%
JM

Jonathan M. Rothberg

Founder & Director

Dr. Jonathan M. Rothberg, Ph. D., is President and Treasurer at identifeye HEALTH Inc. He is Founder of Liminal Sciences, Inc. He is the Chairman and Founder of the 4Catalyzer Corporation. He serves as Director at AI Therapeutics, Inc. He is Co-Founder & Chairman of Protein Evolution, Inc. He is the Founder of Hyperfine Research, Inc. He is the Founder of Quantum-Si incorporated and had been its Executive Chairman since December 2015 and serves as its Executive Director and was its Interim Chief Executive Officer until October 10, 2022 and served as its Interim Chief Executive Officer since February 8, 2022 until February 2022. He serves as Board Member of identifeye HEALTH Inc. (also known as Tesseract Health, Inc.), Founded it and serves as its Board Chair since July 2025. He is the sole Manager of 2012 JMR Trust Common, LLC and has sole voting and investment control of the shares of Class A common stock owned by 2012 JMR Trust Common, LLC. He previously served as Chief Executive Officer at Quantum-Si incorporated from December 2015 to November 2020. Dr. Rothberg is Founder of Hyperfine, Inc. and its Director since 2014 and serves as its Vice Chairman since December 2021. Dr. Rothberg founded Butterfly Network, Inc. in 2011 and serves as its Director since April 24, 2023. He has been Chairman of Legacy Butterfly since February 2021 until April 24, 2023, served as its Interim Chief Executive Officer since December 2022 until April 24, 2023, previously served as its Chief Executive Officer from March 2014 until April 2020 and President from March 2014 to April 2014. Dr. Rothberg served as the Chairman of Legacy Butterfly Board of Directors since March 2014. He previously served as Legacy Butterfly Chief Executive Officer from March 2014 to April 2020 and as Legacy Butterfly President from March 2014 to April 2014. Dr. Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation highest honor for technological achievement, by President Obama for inventing and commercializing high-speed DNA sequencing. Dr. Rothberg is the Founder of the 4Catalyzer medical technology incubator and the Founder and Chairman of its companies: Legacy Butterfly, AI Therapeutics, Incorporated (formerly LAM Therapeutics, Inc.), Hyperfine Research, Inc., 4Bionics LLC, Detect, Incorporated (formerly Homodeus Inc.). These companies focus on using inflection points in medicine, such as deep learning, next-generation sequencing and the silicon supply chain, to address global healthcare challenges. Dr. Rothberg previously founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of Ion Torrent Systems, Incorporated from 2007 to 2010 and founded and served as Chairman and Chief Executive Officer of RainDance Technologies, Incorporated from 2004 to 2009. From 1999 to 2007, Dr. Rothberg co-founded and served as Chairman of ClarifI, Inc. and from 1999 to 2006, he founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of 454 Life Sciences Corporation. With 454 Life Sciences, Dr. Rothberg brought to market the first new way to sequence genomes since Sanger and Gilbert won the Nobel Prize for their method in 1980. With 454 technology, Dr. Rothberg sequenced the first individual human genome and with Svante Paabo he initiated the first large-scale effort to sequence ancient DNA (The Neanderthal Genome Project). Prior to 454 Life Sciences, Dr. Rothberg founded and served as Chairman and Chief Executive Officer of CuraGen Corporation from 1993 to 2004. His contributions to the field of genome sequencing include the first non-bacterial cloning method (cloning by limited dilution) and the first massively parallel DNA sequencing method (parallel sequencing by synthesis on a single substrate), concepts that have formed the basis for all subsequent next generation sequencing technologies. Dr. Rothberg is an Ernst and Young Entrepreneur of the Year, is the recipient of The Wall Street Journal First Gold Medal for Innovation, SXSW Best in Show, Nature Methods First Method of the Year Award, the Connecticut Medal of Technology, the DGKL Biochemical Analysis Prize and an Honorary Doctorate of Science from Mount Sinai. Dr. Rothberg is a Member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, served as a Trustee of Carnegie Mellon University and is an Adjunct Professor of Genetics at Yale University. Dr. Rothberg received his Ph.D., M.Phil. and M.S. in biology from Yale University and his B.S. in chemical engineering from Carnegie Mellon University.

Positions